Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Medical Oncology
•
Cancer Prevention
•
lcis
•
chemoprevention
Is there a role for checking hormone receptor status on LCIS before offering chemoprevention?
Related Questions
How do you decide among AI, full dose tamoxifen and low dose tamoxifen in a postmenopausal woman with DCIS without contraindications to either therapy?
Is there safety data regarding the use of hormonal IUDs in patients with atypical ductal hyperplasia and other high risk, non-malignant breast lesions?
How would you treat a primary angiosarcoma arising in the skull, excised with initial excisional biopsy?
How do you manage a twice-recurrent mucinous adenocarcinoma of the lower eyelid with direct involvement of the lateral rectus muscle and lacrimal duct?
What is your approach to treatment of relapsed, high-risk MDS with TP53 mutation in a patient that is not considered a transplant candidate?
What is your experience with in vitro chemosensitivity testing?
How would you approach a patient with metastatic renal cell carcinoma who developed a STEMI while on TKI (Lenvatinib) and immunotherapy combination?
Is there any data to use PIK3CA-directed agents in mutated metastatic triple-negative breast cancer?
What adjuvant therapy would you recommend for a premenopausal woman with low ER+/PR+ (1-10%) HER2- pT1cN0 metaplastic breast cancer?
How would you decide the duration of ovarian suppression in premenopausal females with early stage ER+ breast cancer?
